Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3342-3354

  Joseph, Aviva ^a   Louria Hayon, Igal ^a   Plis Finarov, Alla ^a   Zeira, Evelyne ^a   Zakay Rones, Zichria ^b   Raz, Eyal ^c   Hayashi, Tomoko ^c   Takabayashi, Kenji ^c   Barenholz, Yechezkel ^b   Kedar, Eli ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Hepatitis B; Influenza; ISS ODN; Liposomes

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; OLIGODEOXYNUCLEOTIDE; SIALIDASE; VIRUS DNA; VIRUS HEMAGGLUTININ;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA SEQUENCE; DRUG CYTOTOXICITY; ENCAPSULATION; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SERUM; SPLEEN CELL; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; DRUG STABILITY; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LIPOSOMES; MACROPHAGES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE; TH1 CELLS; TH2 CELLS;

EID: 0037056027     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00295-5     Document Type: Article

References (69)

1. Raz E., editor. Immunostimulatory DNA sequences (ISS). Springer Semin Immunopathol 2000;22:1-183.
2. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine. 19:2000;618-622.
3. Davis H.L. Use of CpG DNA for enhancing specific immune responses. Curr. Top Microbiol. Immunol. 247:2000;171-183.
4. Van Uden J., Raz E. Introduction to immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22:2000;1-9.
5. Pisetsky D.S. Mechanisms of immune stimulation by bacterial DNA. Springer Semin. Immunopathol. 22:2000;21-33.
6. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2879-2883.
7. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845.
8. Sparwasser T., Koch E.S., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W.et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:1998;2045-2054.
9. Yamamoto S., Yamamoto T., Iho S., Tokunga T. Activation of NK cell (human and mouse) by immunostimulatory DNA sequence. Springer Semin. Immunopathol. 22:2000;35-43.
10. Lipford G.B., Sparwasser T., Bauer M., Zimmermann S., Koch E.S., Heeg K.et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:1997;3420-3426.
11. Klinman D.M., Kamstrup S., Verthelyi D., Gursel I., Ishii K.J., Takeshita F.et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin. Immunopathol. 22:2000;173-183.
12. Martin-Orozco E., Kobayashi H., Van Uden J., Nguyen M.D., Kornbluth R.S., Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 11:1999;1111-1118.
13. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A.et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
14. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
15. Heeg K., Zimmermann S. CpG DNA as a Th1 trigger. Int. Arch. Allergy Immunol. 121:2000;87-97.
16. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine. 18:1999;231-237.
17. Horner A.A., Cinman N., Ronaghy A., Raz E. Mucosal adjuvanticity of immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22:2000;133-146.
18. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigens: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344.
19. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
20. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S.et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18:2000;509-514.
21. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 19:2001;413-422.
22. Krieg A.M., Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3:2001;15-24.
23. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:1998;1216-1224.
24. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:2000;1755-1762.
25. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164:2000;5575-5582.
26. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J.et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:2000;124-134.
27. Horner A.A., Van Uden J.H., Zubeldia J.M., Broide D., Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev. 179:2001;102-118.
28. Krieg A.M., Love-Homan L., Yi A.K., Harty J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:1998;2428-2434.
29. Elkins K.L., Reinehart-Jones T.R., Stibitz S., Conover J.S., Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:1999;2291-2298.
30. Wagner H., Häcker H., Lipford G.B. Immunostimulatory DNA sequences help to eradicate intracellular pathogens. Springer Semin. Immunopathol. 22:2000;147-152.
31. Gramzinski R.A., Doolan D.L., Sedegah M., Davis H.L., Krieg A.M., Hoffman S.L. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 69:2001;1643-1649.
32. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L.et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:2001;4878-4886.
33. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., Hammerling G.J. NK and CD8(+) T cell-mediated eradication of established tumor by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167:2001;5247-5253.
34. Krieg A.M. Signal transduction induced by immunostimulatory CpG DNA. Springer Semin. Immunopathol. 22:2000;97-105.
35. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H.et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
36. Chu W., Gong X., Li Z., Takabayashi K., Ouyang H., Chen Y.et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell. 103:2000;909-918.
37. Wagner H., Lipford G.B., Häcker H. The role of immunostimulatory CpG-DNA in septic shock. Springer Semin. Immunopathol. 22:2000;167-171.
38. Barenholz Y., Crommelin DJA. Liposomes as pharmaceutical dosage forms. In: Swarbrick J, Boylan EC, editors. Encyclopedia of pharmaceutical technology, vol. 9. New York: Marcel Dekker, 1994. p. 1-39.
39. Kersten G.F., Crommelin D.J.A. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta. 1241:1995;117-138.
40. Gregoriadis G., Gürsel I., Gürsel M., McCormack B. Liposomes as immunological adjuvants and vaccine carriers. J. Control. Release. 41:1996;49-56.
41. Alving CR. Liposomes as adjuvants for vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New generation vaccines. 2nd ed. New York: Marcel Dekker, 1997. p. 207-13.
42. Babai I., Samira S., Barenholz Y., Zakay-Rones Z., Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of Th1 and Th2 responses in mice. Vaccine. 17:1999;1239-1250.
43. Kedar E, Barenholz Y. Delivery of cytokines by liposomes: a means of improving their immunomodulatory and anti-tumor activity. In: Chouaib S, editor. The biotherapy of cancers: from immunotherapy to gene therapy. Paris: INSERM, 1998. p. 333-62.
44. Anderson P.M., Hanson D.C., Hasz D.E., Halet M.R., Blazar B.R., Ochoa A.C. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γ Cytokine. 6:1994;92-101.
45. Lachman L.B., Shih L.-C.N., Rao X.-M., Hu X., Bucana C.D., Ullrich S.E.et al. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res. Hum. Retroviruses. 11:1995;921-932.
46. Gregoriadis G., Saffie R., de Souza J.B. Liposome mediated DNA vaccination. FEBS Lett. 401:1997;107-110.
47. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Ann. Rev. Immunol. 18:2000;927-974.
48. Kedar E., Palgi O., Golod G., Babai I., Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNFα show improved pharmacokinetics and biological activity and reduced toxicity in mice. J. Immunother. 20:1997;180-193.
49. Bligh E.J., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:1959;911-917.
50. Barenholz Y, Amselem S. Quality control assays in the development and clinical use of liposome-based formulations. In: Gregoriadis G, editor. Liposome technology, vol. I. 2nd ed. Boca Raton: CRC Press, 1993. p. 527-616.
51. Peterson G.L. Determination of total protein. Methods Enzymol. 91:1983;95-119.
52. Sever J. Application of microtechnique to viral serologic investigation. J. Immunol. 88:1962;321-325.
53. Leshem B., Dorfman Y., Kedar E. Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies. Cancer Immunol. Immunother. 48:1999;179-188.
54. Kedar E., Gur H., Babai I., Samira S., Even-Chen S., Barenholz Y. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J. Immunother. 23:2000;131-145.
55. Gürsel I., Gürsel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167:2001;324-328.
56. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J.et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30:2000;1939-1947.
57. Eastcott J.W., Holmberg C.J., Dewhirst F.E., Esch T.R., Smith D.J., Taubman M.A. Oligonucleotide containing CpG motifs enhances immune responses to mucosally or systemically administered tetanus toxoid. Vaccine. 19:2001;1636-1642.
58. Gürsel M., Tunca S., Özkan M., Özcengiz G., Alaeddinoglu G. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine. 17:1999;1376-1383.
59. Ludewig B., Barchiesi F., Pericin M., Zinkernagel R.M., Hengartner H., Schwendener R.A. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective anti-viral and anti-tumor immunity. Vaccine. 19:2001;23-32.
60. Li W.M., Bally M.B., Schutze-Redelmeier M. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotide encapsulated in liposomes. Vaccine. 20:2001;148-157.
61. Mui B., Raney S.G., Semple S.C., Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 298:2001;1185-1192.
62. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15:1995;317-348.
63. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:2001;3451-3457.
64. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine. 20(Suppl 1):2001;S42-S44.
65. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M.et al. Increased immunogenicity of the MF59 adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17:2001;135-140.
66. Del Guidice G., Padda A., Rappuoli R. What are the limits of adjuvanticity? Vaccine. 20(Suppl 1):2001;S38-S41.
67. Michel M.-L., Pol S., Brechot C., Tiollais P. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future. Vaccine. 19:2001;2395-2399.
68. McCluskie M.J., Weeratna R.D., Davis H.L. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine. 19:2001;2657-2660.
69. Horner A.A., Datta S.K., Takabayashi K., Belyakov I.M., Hayashi T., Cinman N.et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167:2001;1584-1591.